Extract Alpha from Financial Content

AI Infrastructure

AI demand remains substantial, but the market is questioning whether data-center projects can be funded and delivered fast enough to sustain chip growth. Favor demonstrated execution and earnings visibility over headline backlogs; investigation and financing risks keep volatility high.

• ONTO: Beat revenue, earnings, and guidance; management forecasts 45% growth in 2026, making upcoming results an important demand check.
• AMD: Q3 revenue rose 45% and Data Center revenue 97% to $8.55B; Q4 revenue guidance of about $17B supports growth, though semis remain volatile.
• NVDA: Treat as a watchlist holding until the board investigation and China-export questions clarify; reported chip discrepancies and capex concerns cloud the outlook.
• IREN: AI-cloud demand and prepayments are encouraging, but confirm funded, on-time capacity delivery; milestones targeted for January could slip to late February.

Power And Platforms

Data-center electricity needs support power producers, while established consumer and software platforms may be better positioned to monetize AI than leveraged infrastructure builders. Execution, adoption, and project timing remain the key tests.

• VST and CEG: A diversified power basket offers exposure to data-center demand and long-term contracts; verify resilience if projects slow.
• AMZN: Third-party shopping bots could enable agentic commerce, but safeguards against fraud and disputed purchases are essential to protect customers and advertising.
• UBER: Q3 revenue rose 10% to $14.8B and adjusted EPS 35% to $0.88; Q4 EPS guidance of $0.95–$0.99 supports the cash-generative growth case.

Selective Growth

Recent rebounds and selloffs are not reliable entry signals on their own. Strong reported growth can create opportunities, but valuation, durable monetization, and execution deserve confirmation before chasing momentum.

• APP: Revenue grew 55% and free cash flow reached $1.4B, with higher Q4 guidance; assess valuation and competition after a sharp rally.
• NET: Revenue grew 39% and shares jumped 15–18% after hours; watch future guidance for evidence AI adoption sustains growth.
• HIMS: Growth and international expansion are promising, but track subscriber trends, marketing efficiency, and Peptide Plus adoption; retatrutide remains a long-term, approval-dependent possibility.